大柴胡汤(Dachaihu Decoction) - 在研适应症：头痛，肥胖，动脉硬化_专利_临床

概要

基本信息

药物类型

中药

别名

JUNKOU Daisaikoto FC Extract Fine Granules for Ethical Use、OHSUGI Daisaikoto Extract Granules G、OHSUGI Daisaikoto Extract T Tablets

+ [17]

靶点-

作用方式-

作用机制-

治疗领域

免疫系统疾病神经系统疾病心血管疾病+ [4]

在研适应症

头痛肥胖动脉硬化+ [14]

非在研适应症-

原研机构

Sanwa Shoyaku Co., Ltd.

在研机构

Sanwa Shoyaku Co., Ltd.Ohsugi Pharmaceutical Co., Ltd.

非在研机构-

最高研发阶段批准上市

首次获批日期

日本 (1986-07-18),

动脉硬化哮喘胆囊炎+ [12]

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

8

项与大柴胡汤相关的临床试验

NCT06700408

/ Not yet recruiting临床2期IIT

Efficacy and Safety of Dachaihu Decoction Combined Erzhiwan With Variation for the Treatment of Hypercholesterolemia: A Parallel, Randomized, Double-blinded, Placebo-controlled Trial

This is a randomized, double-blind, placebo-controlled clinical trial. Eligible subjects will randomized into a treatment group or placebo group. They will receive either Chinese medicine granules or placebo granules for 8 weeks followed by a 4-week observation period. The primary outcome would be the percent change in Low-density lipoprotein cholesterol levels (LDL-C) after treatment.

开始日期2025-01-01

申办/合作机构

香港中文大学

ITMCTR2024000744

/ SuspendedN/AIIT

Dachaihu decoction combined with Sijin powder for the treatment of liver and gallbladder damp-heat type hypochondriac pain(gallbladder stone disease)---- a double-blind randomized placebo-controlled clinical trial

开始日期2024-12-01

申办/合作机构-

ITMCTR2024000353

/ Suspended临床2/3期IIT

Traditional Chinese medicine Dachaihu decoction ameliorates abnormal behavior through regulating gut microbiota and metabolites in children with ASD

开始日期2024-10-02

申办/合作机构

郑州大学第一附属医院

100 项与大柴胡汤相关的临床结果

登录后查看更多信息

100 项与大柴胡汤相关的转化医学

登录后查看更多信息

100 项与大柴胡汤相关的专利（医药）

登录后查看更多信息

39

项与大柴胡汤相关的文献（医药）

2024-08-01·Current Pharmaceutical Biotechnology

Marine Microalgae Schizochytrium sp. S31: Potential Source for New Antimicrobial and Antibiofilm Agent

Article

作者: Vardar-Yel, Nurcan ; Gurbanov, Rafig ; Hammadi Al-Ogaidi, Doaa Abdullah ; Karaçam, Sevinç

Background:The rise of antibiotic-resistant bacteria necessitates the discovery of new, safe, and bioactive antimicrobial compounds. The antibacterial and antibiofilm activity of microalgae makes them a potential candidate for developing natural antibiotics to limit microbial infection in various fields.Objective:This study aimed to analyze the antibacterial effect of the methanolic extract of Schizochytrium sp. S31 microalgae by broth microdilution and spot plate assays.Methods:The antibacterial effects of Schizochytrium sp. S31 extract was studied on gramnegative pathogens, Pseudomonas aeruginosa, Escherichia coli 35218, Klebsiella pneumonia, which cause many different human infections, and the gram-positive pathogen Streptococcus mutans. At the same time, the antibiofilm activity of the Schizochytrium sp. S31 extract on Pseudomonas aeruginosa and Escherichia coli 35218 bacteria were investigated by crystal violet staining method.Results:Schizochytrium sp. S31 extract at a 60% concentration for 8 hours displayed the highest antibacterial activity against P. aeruginosa, E. coli 35218, and K. pneumonia, with a decrease of 87%, 92%, and 98% in cell viability, respectively. The experiment with Streptococcus mutans revealed a remarkable antibacterial effect at a 60% extract concentration for 24 hours, leading to a notable 93% reduction in cell viability. Furthermore, the extract exhibited a dose-dependent inhibition of biofilm formation in P. aeruginosa and E. coli 35218. The concentration of 60% extract was identified as the most effective dosage in terms of inhibition.Conclusion:This research emphasizes the potential of Schizochytrium sp. S31 as a natural antibacterial and antibiofilm agent with promising applications in the pharmaceutical sectors. This is the first study to examine the antibacterial activity of Schizochytrium sp. S31 microalgae using broth microdilution, spot plate assays, and the antibiofilm activity by a crystal staining method. The findings of this study show that Schizochytrium sp. S31 has antibacterial and antibiofilm activities against critical bacterial pathogens.

2023-12-01·Current Microbiology

Induced Resistance Mechanism of Bacillus velezensis S3-1 Against Pepper Wilt

Article

作者: Jiang, Qiuyan ; Yang, Ning ; He, Xingjie ; Xiao, Ming ; Yu, Yating ; Dai, Jiawei ; Xu, Zhaofeng ; Tang, Xiaorong ; Fan, Yongjie

In recent years, pepper wilt has emerged as a pivotal constraint on pepper yield augmentation. Bacillus velezensis S3-1, with a wide array of hosts, can be used as both a biocontrol agent and biofertilizer. Nonetheless, the precise mechanisms underpinning its employment in combating pepper wilt remain cloaked in ambiguity. In our study, we found that B. velezensis S3-1 could significantly inhibit Fusarium sp. F1^T that caused pepper wilt. S3-1 could effectively inhibit both the growth and germination of F1^T conidia, leading to a reduction in the spore germination percentage from 83.2 to 37.1% in vitro experiments. Additionally, leaf detachment experiments revealed that the volatile compounds produced by S3-1 could inhibit the spread of pepper leaf spot area. Moreover, we observed a significant decrease in the content of malondialdehyde (MDA) in pepper treated with S3-1, along with a significant increase in the content of soluble protein, polyphenol oxidase (PPO), peroxidase (POD), and phenylalanine ammonia-lyase (PAL) in pepper. Furthermore, RT-PCR analysis showed that the expression of the defense genes CaPR 1 and CaPIN II in pepper after treatment with S3-1 was significantly upregulated, suggesting that S3-1 had the potential to induce systemic resistance in pepper, thereby enhancing its disease resistance. Hence, our findings suggest that S3-1 can be a promising biocontrol agent for managing pepper wilt in modern agriculture.

2022-12-01·Gene

Integrated analysis of effect of daisaikoto, a traditional Japanese medicine, on the metabolome and gut microbiome in a mouse model of nonalcoholic fatty liver disease

Article

作者: Yamamoto, Masahiro ; Kaifuchi, Noriko ; Shimobori, Chika ; Iizuka, Seiichi ; Ishizawa, Shiori ; Nahata, Miwa ; Yamada, Chihiro ; Nishi, Akinori ; Nishiyama, Mitsue ; Ohbuchi, Katsuya ; Fujitsuka, Naoki ; Kono, Toru

Dysregulation of lipid metabolism and diabetes are risk factors for nonalcoholic fatty liver disease (NAFLD), and the gut-liver axis and intestinal microbiome are known to be highly associated with the pathogenesis of this disease. In Japan, the traditional medicine daisaikoto (DST) is prescribed for individuals affected by hepatic dysfunction. Herein, we evaluated the therapeutic potential of DST for treating NAFLD through modification of the liver and stool metabolome and microbiome by using STAM mice as a model of NAFLD. STAM mice were fed a high-fat diet with or without 3 % DST for 3 weeks. Plasma and liver of STAM, STAM with DST, and C57BL/6J ("Normal") mice were collected at 9 weeks, and stools at 4, 6, and 9 weeks of age. The liver pathology, metabolome and stool microbiome were analyzed. DST ameliorated the NAFLD activity score of STAM mice and decreased the levels of several liver lipid mediators such as arachidonic acid and its derivatives. In normal mice, nine kinds of family accounted for 94.1 % of microbiome composition; the total percentage of these family was significantly decreased in STAM mice (45.6 %), and DST administration improved this imbalance in microbiome composition (65.2 %). In stool samples, DST increased ursodeoxycholic acid content and altered several amino acids, which were correlated with changes in the gut microbiome and liver metabolites. In summary, DST ameliorates NAFLD by decreasing arachidonic acid metabolism in the liver; this amelioration seems to be associated with crosstalk among components of the liver, intestinal environment, and microbiome.

100 项与大柴胡汤相关的药物交易

登录后查看更多信息

研发状态

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
头痛	日本	Ohsugi Pharmaceutical Co., Ltd.	1986-09-02
肥胖	日本	Ohsugi Pharmaceutical Co., Ltd.	1986-09-02
动脉硬化	日本	Sanwa Shoyaku Co., Ltd.	1986-07-18
哮喘	日本	Sanwa Shoyaku Co., Ltd.	1986-07-18
胆囊炎	日本	Sanwa Shoyaku Co., Ltd.	1986-07-18
胆石症	日本	Sanwa Shoyaku Co., Ltd.	1986-07-18
便秘	日本	Sanwa Shoyaku Co., Ltd.	1986-07-18
胃炎	日本	Sanwa Shoyaku Co., Ltd.	1986-07-18
偏瘫	日本	Sanwa Shoyaku Co., Ltd.	1986-07-18
出血	日本	Sanwa Shoyaku Co., Ltd.	1986-07-18
痔疮	日本	Sanwa Shoyaku Co., Ltd.	1986-07-18
高血压	日本	Sanwa Shoyaku Co., Ltd.	1986-07-18
黄疸	日本	Sanwa Shoyaku Co., Ltd.	1986-07-18
神经痛	日本	Sanwa Shoyaku Co., Ltd.	1986-07-18
神经衰弱	日本	Sanwa Shoyaku Co., Ltd.	1986-07-18
病态肥胖	日本	Sanwa Shoyaku Co., Ltd.	1986-07-18
入睡和睡眠障碍	日本	Sanwa Shoyaku Co., Ltd.	1986-07-18